June was a busy month for the ACIP! The committee approved recommendations for:
- Influenza vaccine for adults 65 and older
- Pneumococcal conjugate vaccine (PCV15) for children
- Moderna COVID-19 vaccine for children and adolescents
Influenza vaccine for adults 65 and older
Health officials have new guidance for older adults just ahead of flu season. The Centers for Disease Control and Prevention (CDC) updated its guidance for adults 65 years and older, and recommended a high-dose or adjuvanted vaccine. The higher dose vaccines can offer greater protection to this group, whose immune system is not as strong as younger and healthier people.
Pneumococcal conjugate vaccine (PCV15) for children
ACIP voted to recommend that Vaxneuvance™ may be used as an option to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) for children younger than 19 years of age, based on currently recommended PCV13 dosing and schedules.
Moderna COVID-19 vaccine for children and adolescents
The CDC signed off on a recommendation of Moderna’s COVID-19 vaccine for ages 6 to 17 years old. The AAP has provided a quick reference guide to help you distinguish between vials. Moderna has used different color caps and has used a different color border around the label. For the six months through 5 years age group the cap is dark blue and the border is magenta. Children ages 6 through 11 the vial has a dark blue cap as well, but the border is purple.
To learn more information regarding the ACIP June meeting click here.
Interested in learning about discounts on your vaccine purchases? Contact CPP Buying Group at cpp@nationwidechildrens.org or call 614-722-2145.